Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.52 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.52 |
| ▸ | OXTR | P30559 | 5/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 7/20 | 0.42 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.32 |
| ▸ | SNRNP200 | O75643 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465123 | 0.90 | AVPR1B (0.62) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL2500531 | 0.84 | BRD4 (0.43) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL2495313 | 0.78 | AVPR1A (0.50) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL5345573 | 0.77 | AVPR1A (0.51) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL1465471 | 0.77 | AVPR1B (0.85) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| Pyridine SCHEMBL5695603 | 0.77 | AVPR1B (0.57) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL1465619 | 0.77 | AVPR1A (0.62) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL5366688 | 0.77 | AVPR1A (0.62) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL1466324 | 0.76 | AVPR1A (0.63) | AVPR1AAVPR1BOXTRAVPR2BRD4 | |
| SCHEMBL2501951 | 0.75 | AVPR1A (0.54) | AVPR1AAVPR1BOXTRAVPR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2017-02-23 | — | — | US | disclosed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8580842-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2546252-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546250-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546251-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-8350055-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20110077241-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110071156-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2011-03-24 | — | — | US | disclosed |
| US-7902379-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | AbbVie Deutschland GmbH & Co. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| EP-1667993-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | Abbott GmbH & Co. KG (DE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030755-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071156-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1A 3/4885AVPR1B 4/4885OXTR 1/4885 |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1A 3/4885AVPR1B 4/4885OXTR 1/4885 |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | OXTR, AVPR2, AVPR1A | AVPR1A 3/4885AVPR1B 4/4885OXTR 1/4885 |
| US-20110077241-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1A 3/4885AVPR1B 4/4885OXTR 1/4885 |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1A 3/4885AVPR1B 4/4885OXTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.